Veracyte (VCYT) Operating Expenses (2012 - 2026)

Veracyte has disclosed Operating Expenses across 15 years of filings, most recently posting $85.6 million for Q2 2026.

• In Q2 2026, Operating Expenses fell 9.96% year-over-year to $85.6 million; the TTM figure through Jun 2026 stood at $297.2 million (down 5.11% YoY), while the FY2025 annual figure was $304.8 million, up 8.07% from the prior year.
• Operating Expenses came in at $85.6 million for Q2 2026 at Veracyte, up from $78.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $100.3 million in Q4 2023 to a low of -$35.1 million in Q4 2022.
• Average Operating Expenses over 5 years is $73.0 million, with a median of $77.6 million recorded in 2025.
• Year-over-year, Operating Expenses plunged 144.1% in 2022 and jumped 385.43% in 2023.
• Over 5 years, Operating Expenses stood at -$35.1 million in 2022, then jumped by 385.43% to $100.3 million in 2023, then declined by 25.64% to $74.6 million in 2024, then fell by 13.14% to $64.8 million in 2025, then soared by 32.1% to $85.6 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $85.6 million in Q2 2026, $78.5 million in Q1 2026, and $64.8 million in Q4 2025.